These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9448080)

  • 1. High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma.
    Kim HK; Lin CC; Parker D; Veals J; Lim J; Likhari P; Statkevich P; Marco A; Nomeir AA
    J Chromatogr B Biomed Sci Appl; 1997 Dec; 703(1-2):225-33. PubMed ID: 9448080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An LC/MS/MS method for the quantitation of MTIC (5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide), a bioconversion product of temozolomide, in rat and dog plasma.
    Chowdhury SK; Laudicina D; Blumenkrantz N; Wirth M; Alton KB
    J Pharm Biomed Anal; 1999 Apr; 19(5):659-68. PubMed ID: 10698531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.
    Reid JM; Stevens DC; Rubin J; Ames MM
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2393-8. PubMed ID: 9815639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma.
    Kim H; Likhari P; Parker D; Statkevich P; Marco A; Lin CC; Nomeir AA
    J Pharm Biomed Anal; 2001 Jan; 24(3):461-8. PubMed ID: 11199225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
    Baker SD; Wirth M; Statkevich P; Reidenberg P; Alton K; Sartorius SE; Dugan M; Cutler D; Batra V; Grochow LB; Donehower RC; Rowinsky EK
    Clin Cancer Res; 1999 Feb; 5(2):309-17. PubMed ID: 10037179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis and stability study of temozolomide using capillary electrophoresis.
    Andrasi M; Bustos R; Gaspar A; Gomez FA; Klekner A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jul; 878(21):1801-8. PubMed ID: 20627825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors.
    Panetta JC; Kirstein MN; Gajjar A; Nair G; Fouladi M; Heideman RL; Wilkinson M; Stewart CF
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):435-41. PubMed ID: 13680158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide.
    Beale P; Judson I; Moore S; Statkevich P; Marco A; Cutler DL; Reidenberg P; Brada M
    Cancer Chemother Pharmacol; 1999; 44(5):389-94. PubMed ID: 10501912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC.
    Kirstein MN; Panetta JC; Gajjar A; Nair G; Iacono LC; Freeman BB; Stewart CF
    Cancer Chemother Pharmacol; 2005 May; 55(5):433-8. PubMed ID: 15818507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition and pharmacokinetics of temozolomide in rat.
    Reyderman L; Statkevich P; Thonoor CM; Patrick J; Batra VK; Wirth M
    Xenobiotica; 2004 May; 34(5):487-500. PubMed ID: 15370964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470.
    Ma J; Pulfer S; Li S; Chu J; Reed K; Gallo JM
    Cancer Res; 2001 Jul; 61(14):5491-8. PubMed ID: 11454697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates.
    Patel M; McCully C; Godwin K; Balis FM
    J Neurooncol; 2003 Feb; 61(3):203-7. PubMed ID: 12675312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide.
    Tsang LL; Quarterman CP; Gescher A; Slack JA
    Cancer Chemother Pharmacol; 1991; 27(5):342-6. PubMed ID: 1998993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-performance liquid chromatographic assay for melphalan in human plasma. Application to pharmacokinetic studies.
    Pinguet F; Joulia JM; Martel P; Grosse PY; Astre C; Bressolle F
    J Chromatogr B Biomed Appl; 1996 Nov; 686(1):43-9. PubMed ID: 8953191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validated high-performance liquid chromatographic assay for simultaneous determination of dacarbazine and the plasma metabolites 5-(3-hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide.
    Safgren SL; Reid JM; Rios R; Ames MM
    J Chromatogr B Biomed Sci Appl; 2001 Apr; 754(1):91-6. PubMed ID: 11318431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
    Aoki T; Nishikawa R; Mizutani T; Nojima K; Mishima K; Adachi J; Matsutani M
    Int J Clin Oncol; 2007 Oct; 12(5):341-9. PubMed ID: 17929115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of simple step protein precipitation UHPLC-MS/MS methods for quantitation of temozolomide in cancer patient plasma samples.
    El Mubarak MA; Stylos EK; Chatziathanasiadou MV; Danika C; Alexiou GA; Tsekeris P; Renziehausen A; Crook T; Syed N; Sivolapenko GB; Tzakos AG
    J Pharm Biomed Anal; 2019 Jan; 162():164-170. PubMed ID: 30243056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
    Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of temozolomide using an extended continuous oral schedule.
    Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
    Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy.
    Ramalho MJ; Andrade S; Coelho MÁN; Loureiro JA; Pereira MC
    Eur J Pharm Biopharm; 2019 Mar; 136():156-163. PubMed ID: 30682492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.